Volastra
Celia Andreu-Agullo currently serves as Senior Director at Volastra Therapeutics since June 2022, previously holding the role of Director of Translational Science and Biomarkers. Prior experience includes working as Principal Scientist in Translational Medicine at Inspirna, Inc. from April 2016 to June 2022, where responsibilities encompassed scientific and strategic support for miRNA-target discovery and analysis of biomarker data from clinical trials. Celia also held the position of Senior Scientist, focusing on preclinical study design and execution. Earlier roles include Research Associate and Research Fellow at MSKCC from April 2009 to April 2016, and serving as a PhD student at the University of Valencia from January 2002 to June 2008.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.